Acumen Pharma (ABOS): Prakiraan rega marang bathi
The high probability of Alzheimer's therapy failure and R&D expenditures create financial instability, which is reflected in the expected P/E metric for Acumen Pharmaceuticals (ABOS), where the figure remains around 0.00. However, the success of Phase 2 and interest from Big Pharma in M&A deals mitigate these risks. Strong confidence among neurologists in the scientific brand of Acumen Pharmaceuticals confirms the asset's long-term potential.
Acumen Pharmaceuticals, Inc (ABOS) - rincian metrik lan laporan keuangan
- kuotasi lan prakiraan analis:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas Acumen Pharmaceuticals|ABOS - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Acumen Pharmaceuticals|ABOS - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Acumen Pharmaceuticals Inc.|ABOS - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Acumen Pharmaceuticals|Rasio cepet acumenpharm.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
ABOS - Bathi resik|Bathi sing dikarepake Acumen Pharmaceuticals|ABOS - Nilai perusahaan marang bathi resik|Rega marang bathi mangsa ngarep Acumen Pharma|ABOS - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Acumen Pharmaceuticals Inc.|ABOS - Bathi operasional EBITDA|Bathi resik saben saham (EPS TTM) Acumen Pharmaceuticals|ABOS - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan acumenpharm.com|ABOS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Acumen Pharmaceuticals
Pambiji fundamental:ABOS Acumen Pharmaceuticals, Inc.
Forward P/E reflects the ratio of current market capitalization to expected net income, allowing investors to assess the value of future earnings and the asset's resilience to macroeconomic shocks. By analyzing changes in the future P/E level of Acumen Pharmaceuticals (ABOS), one can see how the strategic R&D alliance for the development of an Alzheimer's drug reduces financial risks and shapes the fair cost of capital for Acumen Pharmaceuticals.
Analisis pesaing Acumen Pharmaceuticals
Pangali Forward P/E BIIB|Prakiraan rega marang bathi Neurocrine NBIX|Regencell - Prakiraan rega marang bathi|Pangali Forward P/E Axsome Corp AXSM|ACAD - Rega marang bathi mangsa ngarep|xenon-pharma.com (XENE) - Prakiraan rega marang bathi|VKTX: Pangali Forward P/E|Rasio prakiraan rega marang bathi Supernus Pharmaceuticals, Inc. (SUPN)|Rega marang bathi mangsa ngarep Catalyst Pharmaceuticals Inc|Rasio rega marang bathi mangsa ngarep DNLI (Denali Corp)|Prakiraan rega marang bathi HRMY (Harmony Biosciences)|BHVN (biohavenpharma.com) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Amylyx Pharmaceuticals, Inc. AMLX|TRVI (Trevi Therapeutics Inc) - Rasio rega marang bathi sing dikarepake|Praxis Medicines - Pangali Forward P/E|Pangali mangsa ngarep rega marang bathi AVXL (Anavex Life Sciences Corp)|CBLL: Pangali Forward P/E|Prothena (PRTA) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Alector Inc.|ANNX: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Omeros Corporation (OMER)|Prakiraan rega marang bathi Neurogene Therapeutics NGNE|Pangali Forward P/E ACIU (AC Immune)|Pangali Forward P/E voyagertherapeutics.com VYGR|Neumora Therapeutics, Inc. - Pangali Forward P/E|Scilex Holding (SCLX) - Prakiraan rega marang bathi|TVGN: Pangali Forward P/E|Rasio prakiraan rega marang bathi Alpha Cognition Inc. (ACOG)|Prakiraan rega marang bathi CGTX|Pangali Forward P/E inhibikase.com|Prakiraan rega marang bathi SAVA (Cassava Sciences)|Rasio kapitalisasi marang bathi mangsa ngarep ASRT|Pangali Forward P/E COYA (Coya Therapeutics)|Kapitalisasi marang proyeksi bathi VistaGen Therapeutics, Inc. (VTGN)|Ovid Rx - Pangali Forward P/E|cervomed.com (CRVO) - Prakiraan rega marang bathi|ATHE: Pangali Forward P/E|Clene (CLNN) - Pangali Forward P/E|Rega marang bathi mangsa ngarep PepGen Inc|Rega marang bathi mangsa ngarep JUNS|Rega marang bathi mangsa ngarep Relmada Therapeutics (RLMD)|Kapitalisasi marang proyeksi bathi annovisbio.com|Pangali Forward P/E GRCE (Grace Therapeutics)|Pangali Forward P/E Firefly Neuroscience, Inc. AIFF|ANEW Medical, Inc. - Pangali Forward P/E|NRSN: Rega marang bathi mangsa ngarep|Reviva Pharmaceuticals (RVPH) - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi MetaVia (MTVA)|Rega marang bathi mangsa ngarep NeurAxis|Helius Medical Technologies Inc. (HSDT) - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep Passage Bio, Inc. (PASG)|bionomics.com.au - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E NERV (Minerva Neurosciences)|athira.com (ATHA) - Rasio prakiraan rega marang bathi|ADXN: Prakiraan rega marang bathi|ALZN - Pangali Forward P/E|cyclerion.com (CYCN) - Rega marang bathi mangsa ngarep|Protagenic Therapeutics, Inc. - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Pasithea Therapeutics Corp|Rasio prakiraan rega marang bathi Cortigent Medical CRGT|Pangali Forward P/E ATXI|Pangali Forward P/E Brainstorm Cell Therapeutics Inc. (BCLI)|Pangali Forward P/E CARA (Cara Therapeutics, Inc)|CHRO - Prakiraan rega marang bathi|ELYM: Prakiraan rega marang bathi|ITCI - Pangali Forward P/E|Longboard Pharmaceuticals, Inc. (LBPH) - Rega marang bathi mangsa ngarep|Prakiraan rega marang bathi Marinus Pharmaceuticals Inc|NKGN (NKGen) - Pangali Forward P/E|Rasio prakiraan rega marang bathi NeuroBo Pharma NRBO|Rega marang bathi mangsa ngarep Sage Therapeutics, Inc. (SAGE)|synaptogen.com - Rasio rega marang bathi mangsa ngarep|Trevena - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi VIGL|WENA - Rega marang bathi mangsa ngarep|Rasio rega marang bathi sing dikarepake CERE
